Non-Small-Cell Lung Cancer – Epidemiology – Asia-Pacific

Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of NSCLC for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy for the high-income countries.

Clarivate Epidemiology’s NSCLC forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with NSCLC per year?
  • How will improvements in survival change the number of people living with NSCLC?
  • Of all people diagnosed with NSCLC, how many in each of the high-income countries are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NSCLC over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts more than 100 NSCLC patient populations, including the following:

  • Diagnosed incident cases of NSCLC by stage.
  • Diagnosed incident cases of NSCLC by histology.
  • Diagnosed metastatic recurrent incident cases of NSCLC by histology.
  • Diagnosed prevalent cases of NSCLC by histology.
  • Diagnosed first-line NSCLC metastatic drug-treatable population.
  • Diagnosed NSCLC drug-treated populations.

Note: Coverage may vary by country.